Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
615 stopped studies mapped to Melanoma and descendants · 90% state a reason
Over the 615 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05629546 | Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic… | Phase 1 | suspended | Nov 29, 2022 | Washington University School of Medicine | Reviewing safety data | Safety / toxicity |
| NCT05264974 | Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization | Phase 1 | suspended | Mar 3, 2022 | University of Florida | seeking additional funding | Funding |
| NCT05764395 | Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma… | Phase 2 | terminated | Mar 10, 2023 | Vanderbilt-Ingram Cancer Center | Drug unavailable | Other (stated, no rule matched) |
| NCT03804255 | Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision… | — | withdrawn | Jan 15, 2019 | ECOG-ACRIN Cancer Research Group | Study closed before patients enrolled | Enrollment / accrual |
| NCT04866810 | The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN) | N/A | suspended | Apr 30, 2021 | National Cancer Institute (NCI) | On hold pending planned interim analysis. | Efficacy / futility |
| NCT01029873 | QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma | Phase 1 / Phase 2 | terminated | Dec 10, 2009 | Altor BioScience | Sponsor decision | Sponsor / business decision |
| NCT05665595 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for… | Phase 3 | terminated | Dec 27, 2022 | Merck Sharp & Dohme LLC | Business Reason | Sponsor / business decision |
| NCT07076550 | A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408… | Phase 1 | terminated | Jul 22, 2025 | Alpha-9 Oncology USA Inc. | Due to a strategic decision to re-prioritize the sponsor's existing portfolio. | Sponsor / business decision |
| NCT07193966 | NG2 and DLL3 CAR-T Cells Targeting Melanoma | Phase 1 / Phase 2 | terminated | Sep 26, 2025 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT07102212 | Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding…(FOCUS) | N/A | suspended | Aug 3, 2025 | Ohio State University Comprehensive Cancer Center | pending amendment | Other (stated, no rule matched) |
| NCT05308901 | Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve… | Phase 2 | terminated | Apr 4, 2022 | Providence Health & Services | PI opted to close study due to poor accrual. | Enrollment / accrual |
| NCT04899492 | Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy(RESPIRE) | N/A | terminated | May 24, 2021 | Institut Cancerologie de l'Ouest | lack of patient enrolment | Enrollment / accrual |
| NCT03991130 | High Dose IL-2 in Combination With Anti-PD-1 | Phase 2 | terminated | Jun 19, 2019 | Gregory Daniels | Lack of funding | Funding |
| NCT04221438 | Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph… | Phase 2 | terminated | Jan 9, 2020 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT04527549 | Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV… | Phase 2 | terminated | Aug 26, 2020 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT03412058 | Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists(CHECK'UP) | N/A | terminated | Jan 26, 2018 | UNICANCER | The study was terminated prematurely due to insufficient patient recruitment | Enrollment / accrual |
| NCT03178123 | The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma… | Phase 2 | terminated | Jun 6, 2017 | Shanghai Junshi Bioscience Co., Ltd. | The study strategy was adjusted, and the company decided to terminate the study early | Sponsor / business decision |
| NCT03417739 | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | Phase 2 | terminated | Jan 31, 2018 | Dana-Farber Cancer Institute | This was a Simon two stage design trial that terminated after the first stage due to lack of… | Other (stated, no rule matched) |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT03384836 | Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV… | Phase 1 / Phase 2 | suspended | Dec 27, 2017 | Roswell Park Cancer Institute | interim Analysis | Efficacy / futility |
| NCT07614828 | Exploratory Clinical Study of Neoadjuvant Immunotherapy Combined With Chemotherapy in… | Phase 2 | withdrawn | May 29, 2026 | Eye & ENT Hospital of Fudan University | no participants enrolled | Enrollment / accrual |
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Apr 14, 2017 | Novartis Pharmaceuticals | Business reasons and not due to any safety concerns | Safety / toxicity |
| NCT06984328 | Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to… | Phase 2 | terminated | May 22, 2025 | Genmab | Genmab has decided to discontinue further clinical development of acasunlimab following strategic… | Safety / toxicity |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Phase 1 | terminated | Oct 7, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns. | Safety / toxicity |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With… | Phase 1 | suspended | Aug 1, 2023 | University of California, Davis | For internal interim analysis | Efficacy / futility |
| NCT04734704 | Defining the Role of the Skin Microbiome in Immune-related Adverse Events(SKINBIOTA) | N/A | terminated | Feb 2, 2021 | University Hospital, Bordeaux | target number of patients not reached and disabling team changes | Other (stated, no rule matched) |
| NCT04702854 | Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma(BMUMM) | N/A | terminated | Jan 11, 2021 | Centre Hospitalier Universitaire de Nice | recruitment challenges | Enrollment / accrual |
| NCT05130255 | GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 | Phase 1 | terminated | Nov 23, 2021 | Y-mAbs Therapeutics | Decision by Sponsor | Other (stated, no rule matched) |
| NCT01272609 | Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel | Phase 3 | terminated | Jan 10, 2011 | Centre Hospitalier Universitaire de Nice | Rupture du traitement | Other (stated, no rule matched) |
| NCT04695977 | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With… | Phase 2 / Phase 3 | terminated | Jan 6, 2021 | Regeneron Pharmaceuticals | Business Decision | Sponsor / business decision |
| NCT02602756 | Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas(HYGROMEL) | N/A | terminated | Nov 11, 2015 | Centre Antoine Lacassagne | insufficient quality of data collection | Other (stated, no rule matched) |
| NCT04955743 | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal… | Phase 2 | terminated | Jul 9, 2021 | Yale University | Lack of activity in the drugs | Other (stated, no rule matched) |
| NCT03958383 | IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma | Phase 1 / Phase 2 | terminated | May 22, 2019 | University of Wisconsin, Madison | Administrative | Other (stated, no rule matched) |
| NCT06897735 | Exploratory Study of Inhaled Afatinib Dimaleate PK Profile(EDDIS-a1) | Phase 1 | terminated | Mar 27, 2025 | Petrov, Andrey | adjustment of the study design taking into account the receipt of primary data | Other (stated, no rule matched) |
| NCT04168528 | Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT | Phase 1 / Phase 2 | terminated | Nov 19, 2019 | Universitair Ziekenhuis Brussel | Delay in recruitment | Enrollment / accrual |
| NCT06391099 | Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With… | N/A | suspended | Apr 30, 2024 | Ohio State University Comprehensive Cancer Center | pending amendment | Other (stated, no rule matched) |
| NCT04588246 | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to… | Phase 3 | terminated | Oct 19, 2020 | NRG Oncology | Inadequate accrual rate | Enrollment / accrual |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Phase 2 | terminated | Aug 24, 2018 | Iovance Biotherapeutics, Inc. | After reviewing the available safety and efficacy data to date, Iovance concluded that the study… | Safety / toxicity |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced… | Phase 1 | terminated | Mar 11, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced… | Phase 1 / Phase 2 | terminated | May 26, 2021 | M.D. Anderson Cancer Center | PI requested. | Other (stated, no rule matched) |
| NCT02562625 | Trial of Pembrolizumab and Radiotherapy in Melanoma(PERM) | Phase 2 | terminated | Sep 29, 2015 | Royal Marsden NHS Foundation Trust | Slow Recruitment | Enrollment / accrual |
| NCT05341349 | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the… | Phase 1 | terminated | Apr 22, 2022 | Emory University | Slow accrual | Enrollment / accrual |
| NCT06974734 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or… | Phase 1 | terminated | May 16, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT01604889 | A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination… | Phase 1 / Phase 2 | terminated | May 24, 2012 | Incyte Corporation | Further development of this compound with ipilimumab in the treatment of melanoma is no longer… | Other (stated, no rule matched) |
| NCT07092410 | Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive…(SuRage-EB) | Phase 4 | withdrawn | Jul 29, 2025 | SRH Wald-Klinikum Gera GmbH | The study was terminated early due to insufficient patient recruitment. | Enrollment / accrual |
| NCT03699995 | MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma | N/A | terminated | Oct 9, 2018 | OHSU Knight Cancer Institute | The study did not meet its accrual goals due to the departure of study personnel. Study team opted… | Enrollment / accrual |
| NCT02668770 | Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid… | Phase 1 | terminated | Jan 29, 2016 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People… | Phase 1 | terminated | Aug 30, 2024 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and… | Phase 1 | terminated | Feb 5, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 4 days agoSource updated Sep 22, 2026source: clinicaltrials